Millendo Therapeutics (NASDAQ:MLND) Now Covered by Analysts at Wedbush

Wedbush assumed coverage on shares of Millendo Therapeutics (NASDAQ:MLND) in a research note released on Thursday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $24.00 target price on the stock.

MLND has been the topic of several other research reports. Oppenheimer began coverage on Neurocrine Biosciences in a research report on Tuesday, July 16th. They set an outperform rating and a $100.00 target price on the stock. CIBC dropped their target price on Stuart Olson from C$5.00 to C$4.00 in a research report on Tuesday, July 16th. Citigroup set a $12.00 target price on Controladora Vuela Co Avcn SA CV and gave the stock a buy rating in a research report on Monday, July 15th. ValuEngine cut Welbilt from a hold rating to a sell rating in a research report on Wednesday, June 12th. Finally, Zacks Investment Research upgraded Golub Capital BDC from a hold rating to a buy rating and set a $20.00 target price on the stock in a research report on Tuesday, July 16th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Millendo Therapeutics presently has an average rating of Buy and an average price target of $24.38.

Shares of MLND stock opened at $10.51 on Thursday. The firm has a market cap of $140.68 million, a PE ratio of -0.60 and a beta of 2.62. Millendo Therapeutics has a 52-week low of $6.77 and a 52-week high of $17.34. The firm has a 50-day moving average of $12.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83.



Millendo Therapeutics (NASDAQ:MLND) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.08). As a group, equities research analysts predict that Millendo Therapeutics will post -3.27 earnings per share for the current year.

Several large investors have recently made changes to their positions in the company. Great Point Partners LLC purchased a new stake in Millendo Therapeutics in the 4th quarter valued at approximately $10,240,000. Worth Venture Partners LLC purchased a new stake in Millendo Therapeutics in the 4th quarter valued at approximately $206,000. BlackRock Inc. purchased a new stake in Millendo Therapeutics in the 4th quarter valued at approximately $203,000. Tibra Equities Europe Ltd purchased a new stake in Millendo Therapeutics in the 1st quarter valued at approximately $303,000. Finally, Private Advisors LLC lifted its stake in Millendo Therapeutics by 9.1% in the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after buying an additional 1,279 shares in the last quarter. 44.07% of the stock is currently owned by institutional investors and hedge funds.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Read More: How Does the Quiet Period Work?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.